## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Review Proposal Project**

# Review of NICE Technology Appraisal Guidance TA431; Mepolizumab for treating severe refractory eosinophilic asthma

#### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Company/sponsor	General commentators
GlaxoSmithKline (mepolizumab)	All Wales Therapeutics and Toxicology
	Centre
Patient groups	Allied Health Professionals Federation
Action Against Allergy	Board of Community Health Councils in
Allergy UK	Wales
Asthma UK	British National Formulary
British Lung Foundation  Figure 2 of Allegeneral Control of All	Care Quality Commission
European Federation of Allergy and     Ainusy Diseases Patients Association	Department of Health, Social Services     and Bublic Sefety for Northern Iroland
Airway Diseases Patients Association (EFA)	and Public Safety for Northern Ireland
Muslim Council of Britain	<ul> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare Products</li> </ul>
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	<ul> <li>National Association of Primary Care</li> </ul>
The Anaphylaxis Campaign	National Pharmacy Association
1110 / thaphylaxic dampaign	NHS Alliance
Professional groups	NHS Confederation
Association of Respiratory Nurse	Scottish Medicines Consortium
British Geriatrics Society	Welsh Health Specialised Services
British Society for Allergy & Clinical	Committee
Immunology	
British Thoracic Society	<u>Comparators</u>
Primary Care Respiratory Society UK	Novarits
Royal College of General Practitioners	Dalayant naga anah anayan
Royal College of Nursing  Devel College of Path all prints	Relevant research groups
Royal College of Pathologists     Royal College of Physicians	Asthma, Allergy and Inflammation     Research Trust
Royal College of Physicians     Poyal Pharmacoutical Society	British Association for Lung Research
<ul><li>Royal Pharmaceutical Society</li><li>Royal Society of Medicine Specialists</li></ul>	Cochrane Airways Group
UK Clinical Pharmacy Association	Genomics England
- Six Similar Hamilady /18800idilon	MRC Clinical Trials Unit
<u>Others</u>	National Institute for Health Research
Department of Health and Social Care	
NHS Bedfordshire CCG	Associated Public Health Groups
NHS Calderdale CCG	Public Health England
NHS England	Public Health Wales

NICE Technology Appraisal TA431; Mepolizumab for treating severe refractory eosinophilic asthmalssue date: January 2020 © National Institute for Health and Care Excellence 2020 All rights reserved. Subject to Notice of rights. Page 1 of 3

### Welsh Government

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary.

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.